AiCure

MedImmune

MedImmune acquires Definiens, strengthens immuno-oncology capabilities

Wednesday, November 5, 2014 12:55 PM

AstraZeneca’s global biologics R&D arm MedImmune has entered into an agreement to acquire Germany-based Definiens, a privately held company focused on imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of biomarkers in tumor tissue.

More... »


Cancer Innovation forum calls for improving cancer research ecosystem

Monday, October 27, 2014 12:58 PM

Accelerating the delivery of promising new cancer treatments depends on one critical requirement—ensuring patients are actively involved in the cancer research and drug development process from beginning to end.

More... »


Inovio Pharmaceuticals, MedImmune, University of Pennsylvania partner

Wednesday, October 22, 2014 11:39 AM

The Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of PennsylvaniaInovio Pharmaceuticals and MedImmune, the global biologics R&D arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies (mAbs) for infectious disease treatment. DARPA is an agency of the U.S. Department of Defense that creates and supports novel technologies important for national security.

More... »

AstraZeneca, University of Cambridge strengthen partnership

Friday, October 17, 2014 12:46 PM

AstraZeneca, together with its global biologics R&D arm MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership. The latest collaborations reinforce AZ’s commitment to creating a permeable research infrastructure in Cambridge following its decision to locate one of its three global R&D centers and its global headquarters in the city, which has been home to MedImmune’s biologics research laboratories for 25 years.

More... »

Exostar, BT partner

Thursday, October 16, 2014 07:00 AM

Exostar, a Herndon, Va.-based provider of secure, cloud-based solutions that improve collaboration, information sharing and supply chain management for communities of partners, has become a specialist member of the BT for Life Sciences partner ecosystem. Exostar’s secure identity and access management (IAM) and enterprise federation solutions now can be paired with BT’s Workbench Informatics solution for scientists.

More... »

Medimmune, Cancer Research U.K. establish laboratory for biologic cancer medicines

Friday, September 26, 2014 03:24 PM

MedImmune, AstraZeneca’s global biologics R&D arm, and Cancer Research U.K., with its commercial arm Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, U.K. The new laboratory will focus on the discovery and development of novel biologic cancer treatments over an initial five-year period.

More... »

AstraZeneca reveals designs for new U.K. global R&D center, corporate headquarters

Monday, July 21, 2014 03:03 PM

AstraZeneca revealed its proposed designs for its new global R&D center and corporate headquarters in Cambridge, U.K. The facility, which will be located on the Cambridge Biomedical Campus (CBC), includes the global center, an R&D enabling building and an energy center.

More... »

AstraZeneca, Max Planck Institute to create satellite chemistry unit

Wednesday, July 9, 2014 12:03 PM

The Max Planck Institute of Molecular Physiology (MPI), Germany, will establish a satellite unit in cardiovascular and metabolic disease (CVMD) with AstraZeneca's CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.

More... »

Medical Research Council launches U.K. Dementias Research Platform

Thursday, June 19, 2014 01:39 PM

The Medical Research Council (MRC) has launched the U.K. Dementias Research Platform (UKDP), a $27.2 million public-private partnership set up to speed up research into dementias. The collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

More... »

Amgen joins NCI to accelerate development of personalized cancer treatments

Tuesday, June 17, 2014 10:26 AM

Amgen will collaborate with the National Cancer Institute (NCI), part of the NIH, and other public and private sector partners, on the Lung Master Protocol (Lung-MAP), a new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs